SPYRE THERAPEUTICS, INC. (SYRE) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -201.34M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-201.34M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $-201.64M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $-209.56M | $0.00 | (m) | (m) | (m) | (m) |
| 2025-09-30 | $-213.64M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $-212.15M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $-214.36M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-208.57M | $0.00 | (m) | (m) | (m) | (m) |
| 2024-09-30 | $-193.23M | $0.00 | (m) | (m) | (m) | (m) |
| 2024-06-30 | $-156.17M | $0.00 | (m) | (m) | (m) | (m) |
| 2024-03-31 | $-271.27M | $688.00K | (m) | (m) | (m) | -39428.92% |
| 2023-12-31 | $-242.30M | $886.00K | (m) | (m) | (m) | -27347.97% |
| 2023-09-30 | $-215.55M | $1.05M | (m) | (m) | (m) | -20450.76% |
| 2023-06-30 | $-215.97M | $1.23M | (m) | (m) | (m) | -17587.05% |
| 2023-03-31 | $-79.15M | $1.17M | (m) | $55.38M | (m) | -6793.65% |
| 2022-12-31 | $-84.78M | $2.33M | (m) | $58.58M | (m) | -3640.23% |
| 2022-09-30 | $-86.06M | $5.80M | (m) | $61.11M | (m) | -1482.53% |
| 2022-06-30 | $-87.60M | $7.03M | (m) | $63.99M | (m) | -1246.07% |
| 2022-03-31 | $-71.88M | $20.10M | (m) | $62.19M | (m) | -357.60% |
| 2021-12-31 | $-65.65M | $18.74M | (m) | $57.07M | (m) | -350.33% |
| 2021-09-30 | $-67.98M | (m) | (m) | $56.04M | (m) | (m) |
| 2021-06-30 | $-65.81M | (m) | (m) | $53.64M | (m) | (m) |
| 2021-03-31 | $-80.67M | (m) | (m) | $56.93M | (m) | (m) |
| 2020-12-31 | $-81.48M | $0.00 | (m) | $59.64M | (m) | (m) |
| 2020-09-30 | $-80.61M | (m) | (m) | $61.45M | (m) | (m) |
| 2020-06-30 | $-84.64M | (m) | (m) | $66.84M | (m) | (m) |
| 2020-03-31 | $-81.70M | (m) | (m) | $64.77M | (m) | (m) |
| 2019-12-31 | $-80.33M | $0.00 | (m) | $64.60M | (m) | (m) |
| 2019-09-30 | $-73.73M | $0.00 | (m) | $58.83M | (m) | (m) |
| 2019-06-30 | $-63.83M | $0.00 | (m) | $49.92M | (m) | (m) |
| 2019-03-31 | $-54.88M | $2.38M | (m) | $44.24M | (m) | -2307.61% |
| 2018-12-31 | $-45.46M | $3.89M | (m) | $36.72M | (m) | -1169.32% |
| 2018-09-30 | $-36.78M | (m) | (m) | $30.71M | (m) | (m) |
| 2018-06-30 | $-32.54M | (m) | (m) | $28.02M | (m) | (m) |
| 2018-03-31 | $-29.59M | (m) | (m) | $24.74M | (m) | (m) |
| 2017-12-31 | $-27.68M | (m) | (m) | $22.82M | (m) | (m) |
| 2017-09-30 | $-26.59M | (m) | (m) | $21.77M | (m) | (m) |
| 2017-06-30 | $-24.89M | (m) | (m) | $20.91M | (m) | (m) |
| 2017-03-31 | $-23.67M | (m) | (m) | $19.50M | (m) | (m) |
| 2016-12-31 | $-21.91M | (m) | (m) | $18.14M | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-11.31M | (m) | (m) | $11.45M | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-8.90M | (m) | (m) | $6.83M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |